Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 369, Issue 1, pp 23–37 | Cite as

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

  • Ulrich M. ZangerEmail author
  • Sebastian Raimundo
  • Michel Eichelbaum
Review

Abstract

Of about one dozen human P450 s that catalyze biotransformations of xenobiotics, CYP2D6 is one of the more important ones based on the number of its drug substrates. It shows a very high degree of interindividual variability, which is primarily due to the extensive genetic polymorphism that influences expression and function. This so-called debrisoquine/sparteine oxidation polymorphism has been extensively studied in many different populations and over 80 alleles and allele variants have been described. CYP2D6 protein and enzymatic activity is completely absent in less than 1% of Asian people and in up to 10% of Caucasians with two null alleles, which do not encode a functional P450 protein product. The resulting “poor metabolizer” (PM) phenotype is characterized by the inability to use CYP2D6-dependent metabolic pathways for drug elimination, which affect up to 20% of all clinically used drugs. The consequences are increased risk of adverse drug reactions or lack of therapeutic response. Today, genetic testing predicts the PM phenotype with over 99% certainty. At the other extreme, the “Ultrarapid Metabolizer” (UM) phenotype can be caused by alleles carrying multiple gene copies. “Intermediate Metabolizers” (IM) are severely deficient in their metabolism capacity compared to normal “Extensive Metabolizers” (EM), but in contrast to PMs they express a low amount of residual activity due to the presence of at least one partially deficient allele. Whereas the intricate genetics of the CYP2D6 polymorphism is becoming apparent at ever greater detail, applications in clinical practice are still rare. More clinical studies are needed to show where patients benefit from drug dose adjustment based on their genotype. Computational approaches are used to predict and rationalize substrate specificity and enzymatic properties of CYP2D6. Pharmacophore modeling of ligands and protein homology modeling are two complementary approaches that have been applied with some success. CYP2D6 is not only expressed in liver but also in the gut and in brain neurons, where endogenous substrates with high-turnover have been found. Whether and how brain functions may be influenced by polymorphic expression are interesting questions for the future.

Keywords

Pharmacogenetics Pharmacogenomics Ultrarapid metabolizer Intermediate metabolizer Drug oxidation polymorphism Cytochrome P450 Drug metabolism 

Notes

Acknowledgements

This work was supported by grant 01 GG 9846 from the German Federal Ministry of Education and Science and by the Robert Bosch Foundation, Stuttgart, Germany.

References

  1. Agundez JA, Ledesma MC, Ladero JM, Benitez J (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 57:265–269Google Scholar
  2. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441–446Google Scholar
  3. Arcavi L, Benowitz NL (1993) Clinical significance of genetic influences on cardiovascular drug metabolism. Cardiovasc Drugs Ther 7:311–324PubMedGoogle Scholar
  4. Armstrong M, Idle JR, Daly AK (1993) A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. Hum Genet 91:616–617PubMedGoogle Scholar
  5. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet 2:1213–1216CrossRefPubMedGoogle Scholar
  6. Bathum L, Johansson I, Ingelman-Sundberg M, Horder M, Brosen K (1998) Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 8:119–123PubMedGoogle Scholar
  7. Baumann P, Rochat B (1995) Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 10 [Suppl 1]:15–21Google Scholar
  8. Bertilsson L, Eichelbaum M, Mellstrom B, Sawe J, Schulz HU, Sjoqvist F (1980) Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 27:1673–1677CrossRefPubMedGoogle Scholar
  9. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7:478–480PubMedGoogle Scholar
  10. Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341:63Google Scholar
  11. Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209–218PubMedGoogle Scholar
  12. Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO (1996) Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study. Eur J Drug Metab Pharmacokinet 21:309–314PubMedGoogle Scholar
  13. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72:438–452CrossRefPubMedGoogle Scholar
  14. Broly F, Meyer UA (1993) Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 3:123–130PubMedGoogle Scholar
  15. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice JM, Boone P, Meyer UA (1995) An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5:373–384PubMedGoogle Scholar
  16. Brosen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36:537–547PubMedGoogle Scholar
  17. Brosen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 60:312–314PubMedGoogle Scholar
  18. Caporaso N, DeBaun MR, Rothman N (1995) Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics 5:S129–S134PubMedGoogle Scholar
  19. Carcillo JA, Parise RA, Adedoyin A, Frye R, Branch RA, Romkes M (1996) CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers. Res Commun Mol Pathol Pharmacol 91:149–159PubMedGoogle Scholar
  20. Cesaro C, Raimundo S, Klein K, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM (2003) CYP2D6 “Intermediate Metabolizer” phenotype as a consequence of genetically determined alternative splicing. Chem. Listy, Symposia, 97 (2003), Abstract TP41, S137Google Scholar
  21. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ (1996) The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522–534Google Scholar
  22. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ (2000) Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246–251CrossRefPubMedGoogle Scholar
  23. Chou WH, Yan FX, Robbins-Weilert DK, Ryder B, Liu WW, Perbost C, Fairchild M, De Leon J, Koch WH, Wedlund PJ (2003) Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49:542–551PubMedGoogle Scholar
  24. Christensen PM, Gotzsche PC, Brosen K (1997) The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol 51:389–393CrossRefPubMedGoogle Scholar
  25. Christensen PM, Gotzsche PC, Brosen K (1998) The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson’s disease: a meta-analysis. Pharmacogenetics 8:473–479PubMedGoogle Scholar
  26. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nüssler A, Neuhaus P, Zanger UM, Eichelbaum M, Mürdter TE (2002) The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157–167CrossRefPubMedGoogle Scholar
  27. Dahl ML (2002) Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453–470PubMedGoogle Scholar
  28. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F (1995a) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516–520PubMedGoogle Scholar
  29. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, Bertilsson L (1995b) Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 5:159–164PubMedGoogle Scholar
  30. Dalén P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L (1998) 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63:444–452Google Scholar
  31. Daly AK (2003) Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 17:27–41CrossRefPubMedGoogle Scholar
  32. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM (1996a) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193–201PubMedGoogle Scholar
  33. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM (1996b) Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 6:319–328PubMedGoogle Scholar
  34. Daly AK, Steen VM, Fairbrother KS, Idle JR (1996c) CYP2D6 multiallelism. Methods Enzymol 272:199–210PubMedGoogle Scholar
  35. Dayer P, Balant L, Courvoisier F, Kupfer A, Kubli A, Gorgia A, Fabre J (1982) The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet 7:73–77PubMedGoogle Scholar
  36. Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, Eichelbaum M, Meyer UA (1984) Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)—increased Michaelis Constant (Km) and loss of stereoselectivity of bufuralol 1’-hydroxylation in poor metabolizers. Biochem Biophys Res Commun 125:374–380PubMedGoogle Scholar
  37. Dehal SS, Kupfer D (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402–3406PubMedGoogle Scholar
  38. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057–9067PubMedGoogle Scholar
  39. Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE et al (1999) The DNA sequence of human chromosome 22. Nature 402:489–495CrossRefPubMedGoogle Scholar
  40. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects. Pharmacol Ther 46:377–394PubMedGoogle Scholar
  41. Eichelbaum M, Woolhouse NM (1985) Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol 28:79–83PubMedGoogle Scholar
  42. Eichelbaum M, Spannbrucker N, Dengler HJ (1975) Lack of N-oxidation of sparteine in certain healthy subjects. Proceedings of the 6th International Congress of Pharmacology, Helsinki, July 20–25, p 1071Google Scholar
  43. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183–187PubMedGoogle Scholar
  44. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 31:184–186PubMedGoogle Scholar
  45. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C (1986) The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22:49–53PubMedGoogle Scholar
  46. Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C, Rittner C (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 23:455–458PubMedGoogle Scholar
  47. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MM, Simula AP, Ackland MJ, Sternberg MJ, Lennard MS, Tucker GT et al (1995) Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 270:29055–29058CrossRefPubMedGoogle Scholar
  48. Endrizzi K, Fischer J, Klein K, Schwab M, Nüssler AC, Neuhaus P, Eichelbaum M, Zanger UM (2002) Discriminative quantification of CYP2D6 and CYP2D7/8 pseudogene mRNA by TaqMan real-time reverse transcriptase-PCR in human liver. Anal Biochem 300:121–131CrossRefPubMedGoogle Scholar
  49. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491CrossRefPubMedGoogle Scholar
  50. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR (1989) Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 45:568–573PubMedGoogle Scholar
  51. Evert B, Eichelbaum M, Haubruck H, Zanger UM (1997) Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) Expressed by recombinant baculovirus in insect cells. Naunyn-Schmiedebergs Arch Pharmacol 355:309–318Google Scholar
  52. Fonne-Pfister R, Bargetzi MJ, Meyer UA (1987) MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148:1144–1150PubMedGoogle Scholar
  53. Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, Azuma J (2000) The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 380:303–308CrossRefPubMedGoogle Scholar
  54. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48:943–950PubMedGoogle Scholar
  55. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS (1999) Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data [in process citation]. Pharmacogenetics 9:669–682PubMedGoogle Scholar
  56. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC, Wolf CR (1997) Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27:111–125CrossRefPubMedGoogle Scholar
  57. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA (1988a) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442–446PubMedGoogle Scholar
  58. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV, Meyer UA (1988b) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2:174–179PubMedGoogle Scholar
  59. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347:773–776PubMedGoogle Scholar
  60. Gram LF, Brosen K (1993) Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group. Br J Clin Pharmacol 35:649–652PubMedGoogle Scholar
  61. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stüven T, Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15–26PubMedGoogle Scholar
  62. Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M (1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population [in process citation]. Pharmacogenetics 9:715–723PubMedGoogle Scholar
  63. Griese EU, Ilett KF, Kitteringham NR, Eichelbaum M, Powell H, Spargo RM, LeSouef PN, Musk AW, Minchin RF (2001) Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenetics 11:69–76CrossRefPubMedGoogle Scholar
  64. Guengerich FP, Miller GP, Hanna IH, Martin MV, Leger S, Black C, Chauret N, Silva JM, Trimble LA, Yergey JA, Nicoll-Griffith DA (2002) Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 41:11025–11034CrossRefPubMedGoogle Scholar
  65. Guengerich FP, Hanna IH, Martin MV, Gillam EM (2003) Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry 42:1245–1253CrossRefPubMedGoogle Scholar
  66. Guidice JM, Marez D, Sabbagh N, Legrand-Andreoletti M, Spire C, Alcaide E, Lafitte JJ, Broly F (1997) Evidence for CYP2D6 expression in human lung. Biochem Biophys Res Commun 241:79–85CrossRefPubMedGoogle Scholar
  67. Gut J, Catin T, Dayer P, Kronbach T, Zanger U, Meyer UA (1986) Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J Biol Chem 261:11734–11743PubMedGoogle Scholar
  68. Haefeli WE, Bargetzi MJ, Follath F, Meyer UA (1990) Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 15:776–779PubMedGoogle Scholar
  69. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ (1990) The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3’ splice recognition site. Am J Hum Genet 47:994–1001PubMedGoogle Scholar
  70. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529–532PubMedGoogle Scholar
  71. Hiratsuka M, Agatsuma Y, Omori F, Narahara K, Inoue T, Kishikawa Y, Mizugaki M (2000) High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5’ nuclease chain reaction assay. Biol Pharm Bull 23:1131–1135PubMedGoogle Scholar
  72. Hiroi T, Imaoka S, Funae Y (1998) Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249:838–843CrossRefPubMedGoogle Scholar
  73. Huang Z, Fasco MJ, Kaminsky LS (1997) Alternative splicing of CYP2D mRNA in human breast tissue. Arch Biochem Biophys 343:101–108CrossRefPubMedGoogle Scholar
  74. Idle JR, Corchero J, Gonzalez FJ (2000) Medical implications of HGP’s sequence of chromosome 22. Lancet 355:319Google Scholar
  75. Ingelman-Sundberg M (1999) Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Drug Metab Rev 31:449–459CrossRefPubMedGoogle Scholar
  76. Ingelman-Sundberg M, Oscarson M (2002) Human CYP allele database: submission criteria procedures and objectives. Methods Enzymol 357:28–36PubMedGoogle Scholar
  77. Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW (2000) Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics 10:91–93CrossRefPubMedGoogle Scholar
  78. Jackson PR, Tucker GT, Lennard MS, Woods HF (1986) Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 22:541–550PubMedGoogle Scholar
  79. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825–11829PubMedGoogle Scholar
  80. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452–459PubMedGoogle Scholar
  81. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351–355Google Scholar
  82. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209–17214PubMedGoogle Scholar
  83. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS (1982) Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol 13:637–645PubMedGoogle Scholar
  84. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmoller J (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811CrossRefPubMedGoogle Scholar
  85. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45:889–904Google Scholar
  86. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104:173–192PubMedGoogle Scholar
  87. Kivistö KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S–48SGoogle Scholar
  88. Kivistö KT, Griese EU, Stüven T, Fritz P, Friedel G, Kroemer HK, Zanger UM (1997) Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics 7:295–302PubMedGoogle Scholar
  89. Koymans L, Vermeulen NP, van Acker SA, te Koppele JM, Heykants JJ, Lavrijsen K, Meuldermans W, Donne-Op den Kelder GM (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211–219PubMedGoogle Scholar
  90. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M (1989) In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 45:28–33PubMedGoogle Scholar
  91. Kronbach T (1991) Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods Enzymol 206:509–517PubMedGoogle Scholar
  92. Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G (1996) Gene-environment interaction in Parkinson’s disease. The case of CYP2D6 gene polymorphism. Adv Neurol 69:61–72PubMedGoogle Scholar
  93. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK (1998) CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529–541PubMedGoogle Scholar
  94. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF (1982) Oxidation phenotype—a major determinant of metoprolol metabolism and response. N Engl J Med 307:1558–1560PubMedGoogle Scholar
  95. Løvlie R, Daly AK, Molven A, Idle JR, Steen VM (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392:30–34PubMedGoogle Scholar
  96. Løvlie R, Daly AK, Matre GE, Molven A, Steen VM (2001) Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11:45–55CrossRefPubMedGoogle Scholar
  97. Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226:327–338PubMedGoogle Scholar
  98. Madani S, Paine MF, Lewis L, Thummel KE, Shen DD (1999) Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 16:1199–1205CrossRefPubMedGoogle Scholar
  99. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584–256PubMedGoogle Scholar
  100. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193–202PubMedGoogle Scholar
  101. Martinez C, Agundez JA, Gervasini G, Martin R, Benitez J (1997) Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 7:85–93PubMedGoogle Scholar
  102. Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O, Ingelman-Sundberg M (1996) Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 51:117–122Google Scholar
  103. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7:187–191Google Scholar
  104. Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356:1667–1671CrossRefPubMedGoogle Scholar
  105. Meyer UA, Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269–296PubMedGoogle Scholar
  106. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF (2002) Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 82:1376–1387CrossRefPubMedGoogle Scholar
  107. Molden E, Johansen PW, Boe GH, Bergan S, Christensen H, Rugstad HE, Rootwelt H, Reubsaet L, Lehne G (2002) Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. Clin Pharmacol Ther 72:333–342Google Scholar
  108. Murphy GM Jr, Pollock BG, Kirshner MA, Pascoe N, Cheuk W, Mulsant BH, Reynolds CF III (2001) CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25:737–743CrossRefPubMedGoogle Scholar
  109. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52:1034–1040PubMedGoogle Scholar
  110. Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC, Wolf CR (2003) Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021–4027CrossRefPubMedGoogle Scholar
  111. Prueksaritanont T, Dwyer LM, Cribb AE (1995) (+)-Bufuralol 1’-hydroxylation activity in human and rhesus monkey intestine and liver. Biochem Pharmacol 50:1521–1525CrossRefPubMedGoogle Scholar
  112. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM (2000) Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577–581PubMedGoogle Scholar
  113. Raimundo S, Fischer J, Eichelbaum M, Schwab M, Zanger UM (2003) A novel intronic SNP (2988 G>A) directly identifies the common “intermediate metabolizer” allele CYP2D6*41 (submitted).Google Scholar
  114. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12:465–472CrossRefPubMedGoogle Scholar
  115. Raunio H, Hakkola J, Hukkanen J, Pelkonen O, Edwards R, Boobis A, Anttila S (1998) Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl 20:465–469PubMedGoogle Scholar
  116. Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley GN, Smith P, Wilkinson GR, Branch RA (1994) Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis 15:1955–1961PubMedGoogle Scholar
  117. Roots I, Brockmoller J, Drakoulis N, Loddenkemper R (1992) Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Invest 70:307–319Google Scholar
  118. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics 8:227–238PubMedGoogle Scholar
  119. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–295Google Scholar
  120. Schaeffeler E, Schwab M, Eichelbaum M, Zanger M (2003) CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat (in press)Google Scholar
  121. Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618–624PubMedGoogle Scholar
  122. Shin JG, Soukhova N, Flockhart DA (1999) Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 27:1078–1084PubMedGoogle Scholar
  123. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M (2001) Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237–245CrossRefPubMedGoogle Scholar
  124. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC et al (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278–287Google Scholar
  125. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85:5240–5243PubMedGoogle Scholar
  126. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E (1997) Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 51:395–398CrossRefPubMedGoogle Scholar
  127. Steen VM, Molven A, Aarskog NK, Gulbrandsen AK (1995) Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum Mol Genet 4:2251–2257PubMedGoogle Scholar
  128. Steiner E, Iselius L, Alvan G, Lindsten J, Sjoqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38:394–401Google Scholar
  129. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F (1988) Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44:431–435PubMedGoogle Scholar
  130. Stüven T, Griese EU, Kroemer HK, Eichelbaum M, Zanger UM (1996) Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 6:417–421PubMedGoogle Scholar
  131. Syvalahti EK, Lindberg R, Kallio J, De Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22:89–92PubMedGoogle Scholar
  132. Thum T, Borlak J (2000) Gene expression in distinct regions of the heart. Lancet 355:979–983PubMedGoogle Scholar
  133. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1:26–32PubMedGoogle Scholar
  134. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P (1995) Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31:347–353CrossRefPubMedGoogle Scholar
  135. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, Eap CB, Baumann P (2000) Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 855:235–243CrossRefPubMedGoogle Scholar
  136. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410–418Google Scholar
  137. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature (London) 424:464–468Google Scholar
  138. Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, Guengerich FP (1985) Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 45:2116–2122PubMedGoogle Scholar
  139. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J, Werner D, Eschenhagen T (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72:429–437CrossRefPubMedGoogle Scholar
  140. Yamazaki S, Sato K, Suhara K, Sakaguchi M, Mihara K, Omura T (1993) Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s. J Biochem (Tokyo) 114:652–657Google Scholar
  141. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ (1993) Evidence for a new variant CYP2D6 allele CYP2D6 J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 3:256–263Google Scholar
  142. Yu A, Kneller BM, Rettie AE, Haining RL (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303:1291–1300CrossRefPubMedGoogle Scholar
  143. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ (2003a) Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13:173–181CrossRefPubMedGoogle Scholar
  144. Yu AM, Idle JR, Herraiz T, Kupfer A, Gonzalez FJ (2003b) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307–319CrossRefPubMedGoogle Scholar
  145. Zanger UM, Vilbois F, Hardwick JP, Meyer UA (1988a) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27:5447–5454PubMedGoogle Scholar
  146. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA (1988b) Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 85:8256–8260PubMedGoogle Scholar
  147. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573–585CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Ulrich M. Zanger
    • 1
    Email author
  • Sebastian Raimundo
    • 1
  • Michel Eichelbaum
    • 1
  1. 1.Dr. Margarete Fischer-Bosch Institute of Clinical PharmacologyStuttgartGermany

Personalised recommendations